These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27268605)

  • 1. Virological Response to Conventional Interferon Therapy Combined with Ribavirin against Various HCV Genotypes in Khyber Pakhtunkhwa, Pakistan.
    Ali S; Ahmad B; Ali I; Mahmood N; Anwar N; Saeedi I; Afridi JZ
    Asian Pac J Cancer Prev; 2016; 17(5):2407-10. PubMed ID: 27268605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
    Akhtar N; Bilal M; Rizwan M; Khan MA; Khan A
    Asian Pac J Cancer Prev; 2015; 16(3):1037-40. PubMed ID: 25735327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
    Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
    Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong.
    Yuen MF; Lai CL
    Intervirology; 2006; 49(1-2):96-8. PubMed ID: 16166796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Treatment of Untypable HCV Variants in Different Districts of Punjab, Pakistan.
    Zafar A; Imran M; Zahoor S; Shah ZH; Ali M; Afzal MS
    Viral Immunol; 2018; 31(6):426-432. PubMed ID: 29920175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature.
    Haqqi A; Munir R; Khalid M; Khurram M; Zaid M; Ali M; Shah ZH; Ahmed H; Afzal MS
    Viral Immunol; 2019 Nov; 32(9):402-413. PubMed ID: 31556811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases.
    Alavian SM; Tabatabaei SV; Keshvari M; Behnava B; Miri SM; Elizee PK; Lankarani KB
    Liver Int; 2010 Sep; 30(8):1173-80. PubMed ID: 20629950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of interferon alpha with ribavirin for treatment of chronic Hepatitis C].
    Tao J; Liu J; Pu D; Lei H
    Zhonghua Gan Zang Bing Za Zhi; 2011 Sep; 19(9):683-5. PubMed ID: 22152384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimum predictors of therapeutic outcome in HCV patients in Pakistan.
    Aziz H; Raza A; Irfan J
    J Med Virol; 2016 Jan; 88(1):100-8. PubMed ID: 26103918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Declining sustained virological response in hepatitis C.
    Batool U; Qureshi S
    J Coll Physicians Surg Pak; 2006 Mar; 16(3):187-91. PubMed ID: 16542597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis C. Genotypes and response to anti-viral therapy among Saudi patients.
    Al-Traif I; Handoo FA; Al-Jumah A; Al-Nasser M
    Saudi Med J; 2004 Dec; 25(12):1935-8. PubMed ID: 15711670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan.
    Inamullah ; Idrees M; Ahmed H; Sajid-ul-ghafoor ; Ali M; Ali L; Ahmed A
    Virol J; 2011 Jan; 8():16. PubMed ID: 21235746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.